Literature DB >> 24740232

Developing noninvasive diagnosis for single-gene disorders: the role of digital PCR.

Angela N Barrett1, Lyn S Chitty.   

Abstract

Cell-free fetal DNA constitutes approximately 10 % of the cell-free DNA found in maternal plasma and can be used as a reliable source of fetal genetic material for noninvasive prenatal diagnosis (NIPD) from early pregnancy. The relatively high levels of maternal background can make detection of paternally inherited point mutations challenging. Diagnosis of inheritance of autosomal recessive disorders using qPCR is even more challenging due to the high background of mutant maternal allele. Digital PCR is a very sensitive modified method of quantitative real-time PCR (qPCR), allowing absolute quantitation and rare allele detection without the need for standards or normalization. Samples are diluted and then partitioned into a large number of small qPCR reactions, some of which contain the target molecule and some which do not; the proportion of positive reactions can be used to calculate the concentration of targets in the initial sample. Here we discuss the use of digital PCR as an accurate approach to NIPD for single-gene disorders.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24740232     DOI: 10.1007/978-1-4939-0733-5_17

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  3 in total

Review 1.  Current, Emerging, and Future Applications of Digital PCR in Non-Invasive Prenatal Diagnosis.

Authors:  Juliette Nectoux
Journal:  Mol Diagn Ther       Date:  2018-04       Impact factor: 4.074

2.  cfDNA screening and diagnosis of monogenic disorders - where are we heading?

Authors:  Eunice Ka Long Chiu; Winnie Wai In Hui; Rossa Wai Kwun Chiu
Journal:  Prenat Diagn       Date:  2018-01-24       Impact factor: 3.050

3.  A Non-Invasive Droplet Digital PCR (ddPCR) Assay to Detect Paternal CFTR Mutations in the Cell-Free Fetal DNA (cffDNA) of Three Pregnancies at Risk of Cystic Fibrosis via Compound Heterozygosity.

Authors:  Emmanuel Debrand; Alexandra Lykoudi; Elizabeth Bradshaw; Stephanie K Allen
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.